Artykuły udostępnione publicznie: - Einar M. SigurdssonWięcej informacji
Niedostępne w żadnym miejscu: 5
Alzheimer's therapy development: A few points to consider
EM Sigurdsson
Progress in Molecular Biology and Translational Science 168, 205-217, 2019
Upoważnienia: US National Institutes of Health
O2‐05‐01: Immunotherapy targeting Alzheimer's phospho‐tau epitope within the microtubule binding region of tau clears pathological tau and prevents functional decline in a …
PK Krishnamurthy, HB Rajamohamed Sait, A Boutajangout, ...
Alzheimer's & Dementia 5 (4S_Part_4), P112-P112, 2009
Upoważnienia: US National Institutes of Health
P2‐468: In vivo follow‐up of cerebral aging and side effects of anti‐amyloid immunotherapies in the mouse lemur primate
N Joseph‐Mathurin, O Dorieux, A Kraska, M Santin, S Trouche, ...
Alzheimer's & Dementia 7, S462-S463, 2011
Upoważnienia: US National Institutes of Health
IC‐P‐112: MRI of Histological Tissue: Effect of Passive Gadolinium‐Staining
DM Hoang, A Boutajangout, A Bertrand, S Pun, L Fakri-Bouchet, ...
Alzheimer's & Dementia 6, S45-S45, 2010
Upoważnienia: US National Institutes of Health
P2b-16 Evaluation in-vivo par IRM des effets toxiques d’une immunothérapie anti-Alzheimer chez le primate microcèbe murin
N Joseph-Mathurin, A Petiet, P Hantraye, JM Verdier, E Sigurdsson, ...
Revue Neurologique 165 (10), 73-74, 2009
Upoważnienia: US National Institutes of Health
Dostępne w jakimś miejscu: 57
Guidelines for the use and interpretation of assays for monitoring autophagy
DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, ...
Autophagy 8 (4), 445-544, 2012
Upoważnienia: Swiss National Science Foundation, US National Institutes of Health, Howard …
Tau-targeting therapies for Alzheimer disease
EE Congdon, EM Sigurdsson
Nature Reviews Neurology 14 (7), 399-415, 2018
Upoważnienia: US National Institutes of Health
Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain
A Boutajangout, J Ingadottir, P Davies, EM Sigurdsson
Journal of neurochemistry 118 (4), 658-667, 2011
Upoważnienia: US National Institutes of Health
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model
A Boutajangout, D Quartermain, EM Sigurdsson
Journal of Neuroscience 30 (49), 16559-16566, 2010
Upoważnienia: US National Institutes of Health
Tau immunotherapy for Alzheimer's disease
JT Pedersen, EM Sigurdsson
Trends in molecular medicine 21 (6), 394-402, 2015
Upoważnienia: US National Institutes of Health
Extracellular tau oligomers produce an immediate impairment of LTP and memory
M Fá, D Puzzo, R Piacentini, A Staniszewski, H Zhang, MA Baltrons, ...
Scientific reports 6 (1), 19393, 2016
Upoważnienia: US National Institutes of Health, Canadian Institutes of Health Research …
Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance
EE Congdon, J Gu, HBR Sait, EM Sigurdsson
Journal of Biological Chemistry 288 (49), 35452-35465, 2013
Upoważnienia: US National Institutes of Health
Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease
CY Shao, SS Mirra, HBR Sait, TC Sacktor, EM Sigurdsson
Acta neuropathologica 122, 285-292, 2011
Upoważnienia: US National Institutes of Health
Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology
J Gu, EE Congdon, EM Sigurdsson
Journal of Biological Chemistry 288 (46), 33081-33095, 2013
Upoważnienia: US National Institutes of Health
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies
EM Sigurdsson
Journal of Alzheimer’s Disease 15 (2), 157-168, 2008
Upoważnienia: US National Institutes of Health
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's‐disease‐model transgenic mice shown as by micromagnetic resonance imaging
H Scholtzova, YZ Wadghiri, M Douadi, EM Sigurdsson, YS Li, ...
Journal of neuroscience research 86 (12), 2784-2791, 2008
Upoważnienia: US National Institutes of Health
Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments
J Levenga, P Krishnamurthy, H Rajamohamedsait, H Wong, TF Franke, ...
Acta neuropathologica communications 1, 1-14, 2013
Upoważnienia: US National Institutes of Health
Tau-focused immunotherapy for Alzheimer's disease and related tauopathies
EM Sigurdsson
Current Alzheimer Research 6 (5), 446-450, 2009
Upoważnienia: US National Institutes of Health
Tau-targeting therapies for Alzheimer disease: current status and future directions
EE Congdon, C Ji, AM Tetlow, Y Jiang, EM Sigurdsson
Nature Reviews Neurology 19 (12), 715-736, 2023
Upoważnienia: US National Institutes of Health
Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue
HB Rajamohamedsait, EM Sigurdsson
Amyloid Proteins: Methods and Protocols, 411-424, 2012
Upoważnienia: US National Institutes of Health
Informacje na temat publikacji i finansowania automatycznie określa program komputerowy